Silence Therapeutics
SLN
29 hedge funds and large institutions have $102M invested in Silence Therapeutics in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 12 increasing their positions, 5 reducing their positions, and 2 closing their positions.
140% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 5
0.77% more ownership
Funds ownership: 17.07% → 17.84% (+0.77%)
0% more funds holding
Funds holding: 29 → 29 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
8% less capital invested
Capital invested by funds: $110M → $102M (-$8.45M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
+$7.21M |
| 2 |
MCM
M28 Capital Management
Stamford,
Connecticut
|
+$1.31M |
| 3 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
+$973K |
| 4 |
LOAME
Lombard Odier Asset Management (Europe)
London,
United Kingdom
|
+$736K |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$577K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Axa
Paris,
France
|
-$2.76M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.58M |
| 3 |
Goldman Sachs
New York
|
-$1.51M |
| 4 |
WM
WS Management
Jacksonville,
Florida
|
-$155K |
| 5 |
Morgan Stanley
New York
|
-$42.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $3.41K | – | – | – |
|
27
Bank of America
Charlotte,
North Carolina
| $3.02K | – | – | – |
|
|
SPIA
28
Steward Partners Investment Advisory
New York
| $550 | – | – | – |
|
29
Osaic Holdings
Scottsdale,
Arizona
| $27 | +$30 | +5 | New |
|
|
WM
30
WS Management
Jacksonville,
Florida
| – | -$155K | -25,000 | Closed |
|
|
CSS
31
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$16.1K | -2,600 | Closed |
|
SLN Hedge Fund Activity: Q2 2023 in Review
29 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Silence Therapeutics (SLN) for Q2 2023, worth a combined $102M — down 7.7% from $110M a quarter earlier.
Fund positioning in SLN was balanced in Q2 2023: 2 funds opened new positions, 2 closed out, 12 added to existing stakes and 5 trimmed.
The largest buyer was Artal Group, adding an estimated $7.21M. The largest seller was Axa, cutting an estimated $2.76M.
- 29 institutional investors held Silence Therapeutics (SLN) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $102M of Silence Therapeutics stock for Q2 2023, down 7.7% quarter-over-quarter.
- 2 funds opened new Silence Therapeutics positions in Q2 2023 and 2 closed out, a net change of 0 holders.
- The largest Silence Therapeutics buyer in Q2 2023 was Artal Group, an estimated $7.21M added.
- The largest Silence Therapeutics seller in Q2 2023 was Axa, an estimated $2.76M sold.
Based on aggregated 13F filings for Q2 2023.